Muscle spasticity involves the muscles that are tight and can’t be controlled. It is a common symptom of conditions such as cerebral palsy, stroke, and multiple sclerosis. Botulinum toxin type A has emerged as the most effective treatment for muscle spasticity. This toxin works by blocking the signals from nerves to muscles, reducing the stiffness and improving the range of motion. Common botulinum toxin type A products for muscle spasticity treatment include BOTOX, Dysport, and Xeomin.
The global muscle spasticity market is estimated to be valued at US$ 4942.44 million in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Rising Demand for Botulinum Toxin Type A Treatment: As mentioned in the heading, there is a rising demand for botulinum toxin type A treatment worldwide as it has proven to be effective in reducing muscle spasticity. Botulinum toxin relaxes the muscles by blocking acetylcholine, a chemical neurotransmitter, from being released at the neuromuscular junction. This prevents muscles contraction and leads to reduced stiffness. The increasing acceptance of botulinum toxin therapy as the first line treatment is driving the growth of the muscle spasticity market.
Increasing Prevalence of Conditions Causing Spasticity: Spasticity often occurs as a symptom of neurological injuries or diseases such as cerebral palsy, multiple sclerosis, spinal cord injuries, and stroke. With the rising geriatric population worldwide and increasing healthcare infrastructure, there is a growing prevalence of such conditions. This in turn is fueling the demand for treatment of muscle spasticity to improve patient’s quality of life.
The muscle spasticity market can be segmented by type, treatment, and distribution channel. The botulinum toxin segment dominates the market, accounting for over 35% share in 2023. Botulinum toxin effectively treats localized muscle spasticity and is preferred by patients and doctors due to its ability to temporarily paralyze muscles.
Political: The market is positively impacted by increasing regulatory approvals for drugs and treatment devices. However, stringent regulations for approval of new treatments may hamper market growth.
Economic: Rising healthcare spending and growing economy in emerging nations is fueling market expansion. However, high cost of advanced treatments limits market access in low-income regions.
Social: Growing geriatric population and increasing cases of spinal cord injuries and cerebral palsy are driving needs for effective spasticity management.
Technological: Advances in gene therapy and stem cell R&D may offer new avenues. Wearable devices and digital health solutions help monitor symptoms remotely.
The Global Muscle Spasticity Market Size is expected to witness high growth over the forecast period. The global Muscle Spasticity Market is estimated to be valued at US$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030.
North America accounts for over 40% market share currently due to established healthcare systems and stringent rehabilitation practices. However, Asia Pacific market is poised to expand at 8.5% CAGR during the forecast period with China and India emerging as major markets.
Key players operating in the muscle spasticity market are Blackmores Limited, Vitaco Holdings Limited, Integria Healthcare, Bioglan, Deep Blue Health (NZ) Co. Limited, Phytomed, NZ Herbals, and Sanderson. Key players are focusing on new product launches and geographical expansion to strengthen their market presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it